16 results on '"Schuh, Artur Francisco Schumacher"'
Search Results
2. Follow-up of pre-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF
- Author
-
Wilke, Matheus Vernet Machado Bressan, Poswar, Fabiano, Borelli, Wyllians Vendramini, Michelin Tirelli, Kristiane, Randon, Dévora Natalia, Lopes, Franciele Fátima, Pasetto, Fernanda Bender, Sebastião, Fernanda Medeiros, Iop, Gabrielle Dineck, Faqueti, Larissa, da Silva, Layzon Antonio, Kubaski, Francyne, Schuh, Artur Francisco Schumacher, Giugliani, Roberto, and Schwartz, Ida Vanessa Doederlein
- Published
- 2023
- Full Text
- View/download PDF
3. MAY LYSOSOMAL-RELATED GENES BE LINKED TO ATYPICAL PARKINSONISM? A BRAZILIAN STUDY
- Author
-
Schwartz, Ida Vanessa Doederlein, Pasqualotto, Amanda, Schuh, Artur Francisco Schumacher, de Mello Rieder, Carlos Roberto, Sperb-Ludwig, Fernanda, Strelow, Matheus Zschornack, Netto, Alice Brinckmann Oliveira, Facchin, Ana Carolina Brusius, Giugliani, Roberto, and Siebert, Marina
- Published
- 2023
- Full Text
- View/download PDF
4. Life‐space mobility, balance, and self‐efficacy in Parkinson disease: A cross‐sectional study.
- Author
-
Dutra, Ana Carolina Leonardi, Soares, Nayron Medeiros, Artigas, Nathalie Ribeiro, Pereira, Gabriela Magalhães, Krimberg, Julia Schneider, Ovando, Angelica Cristiane, Schuh, Artur Francisco Schumacher, and de Mello Rieder, Carlos Roberto
- Subjects
PARKINSON'S disease ,SELF-efficacy ,MONTREAL Cognitive Assessment ,CROSS-sectional method ,MOVEMENT disorders - Abstract
Background: Life‐space mobility (LSM) is a mobility measure that assesses the physical and social environments through which people move during their daily lives. Objective: To characterize LSM among individuals with Parkinson disease and explore the relationship between LSM, self‐efficacy, and balance. Design: A cross‐sectional study. Settings Movement disorder clinic at a teaching hospital. Participants: Eighty‐eight participants with Parkinson disease. Interventions: Not applicable. Main Outcome Measures: The dependent variable (LSM) was assessed using the Life‐Space Assessment (LSA) instrument. Balance evaluation and balance self‐efficacy were assessed using the Mini Balance Evaluation Systems Test (Mini‐BESTest) and the Activities‐Specific Balance Confidence Scale, respectively. Other variables, such as age, disease staging (Hoehn‐Yahr staging system), cognition (Montreal Cognitive Assessment), and depressive symptoms (Beck Depression Inventory‐II), were also measured. Results: The mean LSA score was 65.2 (SD: 22.8) and mean age was 63.2 years (SD: 10.5 years). Among the 88 patients, 32 (36.4%) were classified as restricted LSM. Age (p =.03), disease severity (p =.02), cognition (p =.02), and motor subtype (p =.006) were associated with more restricted LSM among participants. A multiple linear regression model demonstrated that LSM can be predicted by balance performance (R2 = 0.377; p <.001). Conclusion: Age, disease severity, cognition, motor subtype, balance self‐efficacy, and balance performance are associated with LSM. Understanding and improving balance and self‐efficacy in people with Parkinson disease could facilitate community mobility and promote functional independence and health maintenance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Tracing the distribution of european lactase persistence genotypes along the Americas
- Author
-
Schuh, Artur Francisco Schumacher, Alves, Ana Cecília Guimarães, Borda, Victor, and Beltrame, Márcia Holsbach
- Subjects
Nutrition policies ,América Latina ,Population genetics ,Fenótipo ,Lactose intolerance ,Intolerância à lactose ,Fenômenos genéticos ,+T%22">–13910C > T ,MCM6 gene ,Lactase ,Dairy consumption - Abstract
In adulthood, the ability to digest lactose, the main sugar present in milk of mammals, is a phenotype (lactase persistence) observed in historically herder populations, mainly Northern Europeans, Eastern Africans, and Middle Eastern nomads. As the –13910∗T allele in the MCM6 gene is the most well-characterized allele responsible for the lactase persistence phenotype, the –13910C > T (rs4988235) polymorphism is commonly evaluated in lactase persistence studies. Lactase non-persistent adults may develop symptoms of lactose intolerance when consuming dairy products. In the Americas, there is no evidence of the consumption of these products until the arrival of Europeans. However, several American countries’ dietary guidelines recommend consuming dairy for adequate human nutrition and health promotion. Considering the extensive use of dairy and the complex ancestry of Pan-American admixed populations, we studied the distribution of –13910C > T lactase persistence genotypes and its flanking haplotypes of European origin in 7,428 individuals from several Pan-American admixed populations. We found that the –13910∗T allele frequency in Pan-American admixed populations is directly correlated with allele frequency of the European sources. Moreover, we did not observe any overrepresentation of European haplotypes in the –13910C > T flanking region, suggesting no selective pressure after admixture in the Americas. Finally, considering the dominant effect of the –13910∗T allele, our results indicate that Pan-American admixed populations are likely to have higher frequency of lactose intolerance, suggesting that general dietary guidelines deserve further evaluation across the continent.
- Published
- 2021
6. Genética da doença de Parkinson no Brasil : revisão sistemática de formas monogênicas
- Author
-
Lobato, Bruno Lopes dos Santos, Schuh, Artur Francisco Schumacher, Mata, Ignacio Fernandez, Letro, Grace Helena, Braga Neto, Pedro, Brandão, Pedro Renato de Paula, Godeiro Júnior, Clécio de Oliveira, Coletta, Marcus Vinicius Della, Camargos, Sarah Teixeira, Borges, Vanderci, Rieder, Carlos Roberto de Mello, and Tumas, Vitor
- Subjects
Predisposição genética para doença ,Genetics ,Parkinson’s disease ,LRRK2 ,PRKN ,Doença de Parkinson ,Genética ,Mutação - Abstract
Introdução: Um número crescente de mutações causando formas monogênicas de doença de Parkinson (DP) tem sido descrito, principalmente entre pacientes da Europa e da América do Norte. Como a arquitetura genética varia entre diferentes populações, entender os perfis genéticos específicos de pacientes brasileiros é essencial para um melhor aconselhamento genético e para a seleção de participantes para ensaios clínicos. Objetivo: Revisão sistemática para identificar estudos genéticos brasileiros na área e definir o cenário para estudos futuros das formas monogênicas de DP no Brasil. Métodos: Nós pesquisamos as bases de dados MEDLINE, EMBASE e Web of Science desde a criação até dezembro de 2019, usando termos para “Parkinson’s disease”, “genetics” e “Brazil”. A extração de dados foi feita por dois revisores independentes. Para os genes LRRK2 e PRKN, calculamos a prevalência estimada para cada estudo e realizamos uma meta-análise. Resultados: Um total de 32 estudos foram incluídos e 94 pacientes brasileiros com DP com mutações causativas foram identificados em 2872 pacientes avaliados (3.2%). As mutações no PRKN causaram DP em 48 de 576 pacientes (8.3%). As mutações no LRRK2 foram identificadas em 40 de 1566 pacientes (2.5%), sendo a mutação mais comum a p.G2019S (2.2%). Conclusões: As mutações na PRKN são a causa mais comum de DP autossômica recessiva, e as mutações no LRRK2 a causa mais comum de DP autossômica dominante. Nós observamos uma falta de estudos epidemiológicos robustos em genética de DP, especialmente por não levar em conta a diversidade de nossa população. Background: Increasing numbers of mutations causing monogenic forms of Parkinson's disease (PD) have been described, mostly among patients in Europe and North America. Since genetic architecture varies between different populations, studying the specific genetic profile of Brazilian patients is essential for improving genetic counseling and for selecting patients for clinical trials. Objective: We conducted a systematic review to identify genetic studies on Brazilian patients and to set a background for future studies on monogenic forms of PD in Brazil. Methods: We searched MEDLINE, EMBASE and Web of Science from inception to December 2019 using terms for "Parkinson's disease", "genetics" and "Brazil". Two independent reviewers extracted the data. For the genes LRRK2 and PRKN, the estimated prevalence was calculated for each study, and a meta-analysis was performed. Results: A total of 32 studies were included, comprising 94 Brazilian patients with PD with a causative mutation, identified from among 2,872 screened patients (3.2%). PRKN mutations were causative of PD in 48 patients out of 576 (8.3%). LRRK2 mutations were identified in 40 out of 1,556 patients (2.5%), and p.G2019S was the most common mutation (2.2%). Conclusions: PRKN is the most common autosomal recessive cause of PD, and LRRK2 is the most common autosomal dominant form. We observed that there was a lack of robust epidemiological studies on PD genetics in Brazil and, especially, that the diversity of Brazil’s population had not been considered.
- Published
- 2021
7. Interleukin-6 Serum Levels in Patients with Parkinson’s Disease
- Author
-
Hofmann, Kerly Wollmeister, Schuh, Artur Francisco Schumacher, Saute, Jonas, Townsend, Raquel, Fricke, Daniele, Leke, Renata, Souza, Diogo O., Portela, Luis Valmor, Chaves, Márcia Lorena Fagundes, and Rieder, Carlos R. M.
- Published
- 2009
- Full Text
- View/download PDF
8. Modelo de predição diagnóstica para discinesias induzidas por levodopa na doença de Parkinson
- Author
-
Lobato, Bruno Lopes dos Santos, Schuh, Artur Francisco Schumacher, Rieder, Carlos Roberto de Mello, Hutz, Mara Helena, Borges, Vanderci, Ferraz, Henrique Ballalai, Mata, Ignacio Fernandez, Zabetian, Cyrus P., and Tumas, Vitor
- Subjects
Levodopa ,Parkinson disease ,Dyskinesia ,Antiparkinsonianos ,Decision support techniques ,Discinesia induzida por medicamentos ,Polimorfismo de nucleotídeo único - Abstract
Introdução: No momento, não há métodos para se predizer o desenvolvimento de discinesias induzidas por levodopa (DIL), uma frequente complicação do tratamento da doença de Parkinson (DP). Preditores clínicos e polimorfismos de nucleotídeo único (SNP) têm sido associados às DIL na DP. Objetivo: Investigar a associação entre variáveis clínicas e genéticas com as DIL e desenvolver um modelo de predição diagnóstica de DIL na DP. Métodos: Foram avaliados 430 pacientes com DP em uso de levodopa. A presença de DIL foi definida como escore ≥1 no item 4.1 da MDS-UPDRS Parte IV. Nós testamos a associação entre variáveis clínicas específicas e sete SNPs com o desenvolvimento de DIL, usando modelos de regressão logística. Resultados: Em relação às variáveis clínicas, idade de início da doença, duração da doença, sintomas motores iniciais e uso de agonistas dopaminérgicos estiveram associados às DIL. Apenas o genótipo CC do SNP rs2298383 no gene ADORA2A esteve associado com DIL após o ajuste. Nós desenvolvemos dois modelos preditivos diagnósticos com acurácia razoável, mas sugerimos o uso do modelo preditivo clínico. Esse modelo de predição tem uma área sob a curva de 0,817 (intervalo de confiança de 95% [IC95%] 0,77‒0,85) e sem perda significativa de ajuste (teste de qualidade de ajuste de Hosmer-Lemeshow p=0,61). Conclusão: A probabilidade prevista de DIL pode ser estimada, com acurácia razoável, por meio do uso de um modelo preditivo diagnóstico clínico, que combina a idade de início da doença, duração da doença, sintomas motores iniciais e uso de agonistas dopaminérgicos. Background: There are currently no methods to predict the development of levodopa-induced dyskinesia (LID), a frequent complication of Parkinson's disease (PD) treatment. Clinical predictors and single nucleotide polymorphisms (SNP) have been associated to LID in PD. Objective: To investigate the association of clinical and genetic variables with LID and to develop a diagnostic prediction model for LID in PD. Methods: We studied 430 PD patients using levodopa. The presence of LID was defined as an MDS-UPDRS Part IV score ≥1 on item 4.1. We tested the association between specific clinical variables and seven SNPs and the development of LID, using logistic regression models. Results: Regarding clinical variables, age of PD onset, disease duration, initial motor symptom and use of dopaminergic agonists were associated to LID. Only CC genotype of ADORA2A rs2298383 SNP was associated to LID after adjustment. We developed two diagnostic prediction models with reasonable accuracy, but we suggest that the clinical prediction model be used. This prediction model has an area under the curve of 0.817 (95% confidence interval [95%CI] 0.77‒0.85) and no significant lack of fit (Hosmer-Lemeshow goodness-of-fit test p=0.61). Conclusion: Predicted probability of LID can be estimated with reasonable accuracy using a diagnostic clinical prediction model which combines age of PD onset, disease duration, initial motor symptom and use of dopaminergic agonists.
- Published
- 2020
9. The Parkinson's Disease genome-wide association study locus browser
- Author
-
Schuh, Artur Francisco Schumacher, Grenn, Francis P., and Blauwendraat, Cornelis
- Subjects
Prioritization ,Fatores de risco ,Predisposição genética para doença ,Idade de início ,Parkinson’s disease ,GWAS ,Doença de Parkinson ,Estudo de associação genômica ampla - Abstract
Background: Parkinson's disease (PD) is a neurodegenerative disease with an often complex component identifiable by genome-wide association studies. The most recent large-scale PD genome-wide association studies have identified more than 90 independent risk variants for PD risk and progression across more than 80 genomic regions. One major challenge in current genomics is the identification of the causal gene(s) and variant(s) at each genome-wide association study locus. The objective of the current study was to create a tool that would display data for relevant PD risk loci and provide guidance with the prioritization of causal genes and potential mechanisms at each locus. Methods: We included all significant genome-wide signals from multiple recent PD genome-wide association studies including themost recent PD risk genome-wide association study, age-at-onset genome-wide association study, progression genome-wide association study, and Asian population PD risk genome-wide association study. We gathered data for all genes 1 Mb up and downstream of each variant to allow users to assess which gene(s) are most associated with the variant of interest based on a set of self-ranked criteria. Multiple databases were queried for each gene to collect additional causal data. Results: We created a PD genome-wide association study browser tool (https://pdgenetics.shinyapps.io/GWASBrowser/) to assist the PD research community with the prioritization of genes for follow-up functional studies to identify potential therapeutic targets. Conclusions: Our PD genome-wide association study browser tool provides users with a useful method of identifying potential causal genes at all known PD risk loci from large-scale PD genome-wide association studies. We plan to update this tool with new relevant data as sample sizes increase and new PD risk loci are discovered.
- Published
- 2020
10. Validação do questionário de 19 itens de wearing-off (WOQ-19) para a língua portuguesa
- Author
-
Mantese, Carlos Eduardo Aliatti, Medeiros, Márcio Schneider, Schuh, Artur Francisco Schumacher, and Rieder, Carlos Roberto de Mello
- Subjects
Antiparkinson Agents ,Inquéritos e questionários ,Qualidade de vida ,Reprodutibilidade dos testes ,Parkinson Disease ,Doença de Parkinson - Abstract
Introdução: O tratamento da doença de Parkinson com terapia dopaminérgica melhora a funcionalidade e a qualidade de vida. Entretanto, com a progressão da doença, os fenômenos de flutuação motora e não motora se desenvolvem. Para melhorar o reconhecimento dessa situação, foi desenvolvido o questionário de 19 itens de wearing-off (WOQ-19) Objetivo: Traduzir e validar o questionário WOQ-19 para a língua portuguesa. Métodos: O questionário foi traduzido do inglês para o português. Em seguida, foi retrotraduzido para o inglês e analisado. A versão final foi testada em pacientes parkinsonianos com paradigma teste-reteste e consistência interna. A sensibilidade e especificidade foram medidas em relação a vários pontos de cortes de itens positivos. Resultados: O questionário apresenta boa estabilidade de teste, com coeficiente de correlação intraclasse de 0,877 (IC95% 0,690-0,951; p
- Published
- 2020
11. Clinimetrics of the 9- and 19-item wearing-off questionnaire : a systematic review
- Author
-
Mantese, Carlos Eduardo Aliatti, Schuh, Artur Francisco Schumacher, and Rieder, Carlos Roberto de Mello
- Subjects
Inquéritos e questionários ,Doença de Parkinson ,Tratamento farmacológico - Abstract
The treatment of Parkinson’s disease (PD) with dopaminergic therapy improves functionality and quality of life. However, as the disease progresses, the wearing-off phenomenon develops, which necessitates complex posology adjustment or adjuvant therapy. This phenomenon may not be well recognized, especially if it is mild or involves nonmotor symptoms. Questionnaires were developed to improve the recognition of the wearing-off phenomenon. The questionnaires consist of a list of symptoms that patients must check if they have and if the symptoms improve with medication. A recent review by the Movement Disorder Society suggested the 19-item (WOQ-19) and 9-item (WOQ-9) questionnaires as screening tools for the wearing-off phenomenon. However, there has not been a systematic review to assess the questionnaires’ clinimetric properties, such as sensitivity, specificity, test-retest reliability, and responsiveness. We conducted an extensive search for studies using these two tools. We identified 3 studies using WOQ-19 and 5 studies using WOQ-9. Both questionnaires seem to have good sensitivity (0.81–1). WOQ-19 has variable specificity (0.39–0.8), depending on the number of positive items, while WOQ-9 lacks specificity (0.1–0.69). Only one study using WOQ-19 reported test-retest, and only two studies reported responsiveness. Thus, this report describes the first independent systematic review to exam quantitatively the clinimetric properties of these two questionnaires.
- Published
- 2018
12. Clinical and Epidemiological Factors Associated with Mortality in Parkinson’s Disease in a Brazilian Cohort.
- Author
-
Fernandes, Gustavo Costa, Socal, Mariana Peixoto, Schuh, Artur Francisco Schumacher, and Rieder, Carlos R. M.
- Subjects
AGE factors in disease ,MORTALITY ,PARKINSON'S disease ,POPULATION ,STATISTICS ,COMORBIDITY ,MEDICAL records ,PROPORTIONAL hazards models ,DESCRIPTIVE statistics - Abstract
Background. Prognosis of PD is variable. Most studies show higher mortality rates in PD patients compared to the general population. Clinical and epidemiologic factors predicting mortality are poorly understood. Methods. Clinical and epidemiologic features including patient history and physical, functional, and cognitive scores were collected from a hospital-based cohort of PD patients using standardized protocols and clinical scales. Data on comorbidities and mortality were collected on follow-up. Results. During a mean follow-up of 4.71 years (range 1–10), 43 (20.9%) of the 206 patients died. Those who died had higher mean age at disease onset than those still alive at the last follow-up (67.7 years versus 56.3 years; p<0.01). In the univariate analysis, age at baseline was associated with decreased survival. In the adjusted Cox proportional hazards model, age at disease onset and race/ethnicity were predictors of mortality. Conclusions. Late age at disease onset and advanced chronological age are associated with decreased survival. Comorbidities and PD characteristics were not associated with decreased survival in our sample. Race/ethnicity was found in our study to be associated with increased hazard of mortality. Our findings indicate the importance of studying survival among different populations of PD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. A systematic review and meta-analysis of the prevalence of Parkinson's disease in lower to upper-middle-income countries.
- Author
-
Pereira GM, Teixeira-Dos-Santos D, Soares NM, Marconi GA, Friedrich DC, Saffie Awad P, Santos-Lobato BL, Brandão PRP, Noyce AJ, Marras C, Mata IF, Rieder CRM, and Schuh AFS
- Abstract
Parkinson's disease (PD) is a common neurodegenerative disease that is a growing public health challenge. Estimates of the burden of PD have focused on data from high-income countries, with lower-income countries poorly described. We reviewed and examined the prevalence of PD reported by studies in low- to upper-middle-income countries. A systematic literature search was performed in the Medline/PubMed, Embase, LILACS, and Web of Science databases. Age group, sex, and geographic region were considered when analyzing the data. Of the 4327 assessed articles, 57 met the inclusion criteria for qualitative review, and 36 were included in the meta-analysis. Heterogeneity measures were high both as a whole and in each geographic region. Data analysis by geographic region showed that reported prevalence differed across regions, ranging from 49 per 100,000 (Sub-Saharan Africa) to 1081 per 100,000 (Latin America and the Caribbean). There was an increasing prevalence of PD with advancing age (per 100,000): 7 in 40-49 years, 158 in 50-59 years, 603 in 60-69 years, 1251 in 70-79 years, and 2181 in over the age of 80. The prevalence of PD in men and women was similar. There was a greater PD prevalence in populations with a higher 5-year GDP per capita and a higher life expectancy. Our findings suggest a higher prevalence of PD in lower and upper-middle-income countries than previously reported. Comparisons between regions are difficult, as the sociocultural differences and lack of methodological standardization hinder understanding key epidemiological data in varied populations., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Life-space mobility, balance, and self-efficacy in Parkinson disease: A cross-sectional study.
- Author
-
Dutra ACL, Soares NM, Artigas NR, Pereira GM, Krimberg JS, Ovando AC, Schuh AFS, and de Mello Rieder CR
- Subjects
- Humans, Middle Aged, Cross-Sectional Studies, Self Efficacy, Physical Therapy Modalities, Cognition, Postural Balance, Parkinson Disease
- Abstract
Background: Life-space mobility (LSM) is a mobility measure that assesses the physical and social environments through which people move during their daily lives., Objective: To characterize LSM among individuals with Parkinson disease and explore the relationship between LSM, self-efficacy, and balance., Design: A cross-sectional study., Settings: Movement disorder clinic at a teaching hospital., Participants: Eighty-eight participants with Parkinson disease., Interventions: Not applicable., Main Outcome Measures: The dependent variable (LSM) was assessed using the Life-Space Assessment (LSA) instrument. Balance evaluation and balance self-efficacy were assessed using the Mini Balance Evaluation Systems Test (Mini-BESTest) and the Activities-Specific Balance Confidence Scale, respectively. Other variables, such as age, disease staging (Hoehn-Yahr staging system), cognition (Montreal Cognitive Assessment), and depressive symptoms (Beck Depression Inventory-II), were also measured., Results: The mean LSA score was 65.2 (SD: 22.8) and mean age was 63.2 years (SD: 10.5 years). Among the 88 patients, 32 (36.4%) were classified as restricted LSM. Age (p = .03), disease severity (p = .02), cognition (p = .02), and motor subtype (p = .006) were associated with more restricted LSM among participants. A multiple linear regression model demonstrated that LSM can be predicted by balance performance (R
2 = 0.377; p < .001)., Conclusion: Age, disease severity, cognition, motor subtype, balance self-efficacy, and balance performance are associated with LSM. Understanding and improving balance and self-efficacy in people with Parkinson disease could facilitate community mobility and promote functional independence and health maintenance., (© 2022 American Academy of Physical Medicine and Rehabilitation.)- Published
- 2023
- Full Text
- View/download PDF
15. The impact of cognitive performance on quality of life in individuals with Parkinson's disease.
- Author
-
Olchik MR, Ayres A, Ghisi M, Schuh AFS, and Rieder CRM
- Abstract
Background: Evidence points to the occurrence of cognitive impairment in all stages of PD, constituting a frequent and debilitating symptom, due to high impact on quality of life and mortality of patients., Objective: To correlate cognitive performance with quality of life in PD., Methods: The sample was drawn from a Movement Disorders Clinic of a reference hospital in Porto Alegre. Inclusion criteria were: PD diagnosis, according to the United Kingdom Parkinson's Disease Society Brain Bank criteria for idiopathic PD (Hughes et al. 1992) and patient consent to participate. Patients with other neurological pathologies and those submitted to deep brain stimulation were excluded. The evaluation consisted of a cognitive testing battery (composed of eight tests for assessing cognitive performance), and a questionnaire on quality of life (PDQ-39) and depression (BDI)., Results: The sample comprised 85 individuals with PD, with a mean age of 62.9 years (±10.7), mean disease duration of 10.4 years (±5.7), and mean educational level of four years (±4.3). There was a significant relationship between total score on the PDQ and all cognitive tests, showing that poor cognitive performance was correlated with poor quality of life. Moreover, a significant correlation was observed between cognitive tests and depression, H&Y, education level, and age., Conclusion: It may be concluded that the individuals with PD in this sample showed a correlation between poorer quality of life and worse cognitive performance. Poor performance was also correlated with more advanced stage, older age, low level of education and depression., Competing Interests: Disclosure: The authors report no conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
16. The Impact of Dysphagia Therapy on Quality of Life in Patients with Parkinson's Disease as Measured by the Swallowing Quality of Life Questionnaire (SWALQOL).
- Author
-
Ayres A, Jotz GP, Rieder CR, Schuh AF, and Olchik MR
- Abstract
Introduction: Dysphagia is a common symptom in Parkinson's disease (PD) and it has been associated with poor quality of life (QoL), anxiety, depression., Objective: The aim of this study was to evaluate the quality of life in individuals with PD before and after SLP therapy., Methods: The program consisted of four individual therapy sessions. Each session comprised guidelines regarding food and postural maneuvers (chin down). The Quality of Life in Swallowing Disorders (SWAL-QOL) questionnaire was applied before and after therapy., Results: The sample comprised of 10 individuals (8 men), with a mean (SD) age of 62.2 (11.3) years, mean educational attainment of 7.5 (4.3) years, and mean disease duration of 10.7 (4.7) years. Thirty percent of patients were Hoehn and Yahr (H&Y) stage 2, 50% were H&Y stage 3, and 20% were H&Y stage 4. Mean scores for all SWAL-QOL domains increased after the intervention period, with significant pre- to post-therapy differences in total score (p = 0.033) and domain 4 (symptom frequency) (p = 0.025). There was also a bias significance for domain 5 (food selection) (p = 0.095)., Conclusion: Patients exhibited improvement in swallowing-related quality of life after a SLP therapy program. The earlier in the course of PD, greater the improvement observed after therapy.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.